The trajectory of Sildenafil presents a interesting case for investors in the drug sector. While initially a phenomenal success, producing billions, the intellectual property lapse and the subsequent arrival of cheaper competitors have drastically affected income. This poses questions about the long-term viability of related drug innovations and… Read More